CYP2D6遗传多态性对坦苏洛辛在患有良性前列腺增生症的患者的疗效和安全性产生影响
Shokhrukh Abdullaev1,2, Maksim Shatokhin1,3, Ivan Sychev1,4
1Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Drug metabolism and personalized therapy
|February 13, 2025
概括
由于良性前列腺增生 (BPH) 导致的下泌尿道症状 (LUTS) 的tamsulosin治疗可以通过CYP2D6遗传变异和患者因素来预测. 这些标志物,包括CYP2D6*4,*10,*41,BMI和前列腺体积,可以帮助个性化治疗以改善结果.
科学领域:
- 药物遗传学 药物遗传学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 内部医学 内部医学
背景情况:
- 对于LUTS/BPH患者的tamsulosin治疗的临床结果表现出显著的变化.
- 鉴定tamsulosin疗效的预测因素对于优化LUTS/BPH患者治疗至关重要.
- 基因多态性CYP2D6在tamsulosin反应中的作用需要进一步研究.
研究的目的:
- 评估CYP2D6药物遗传标记对塔姆苏洛辛有效性和安全性的影响.
- 确定与BPH相关的LUTS患者的坦苏洛辛治疗有效性的潜在预测因素.
主要方法:
- 在8周内评估了142名患有LUTS/BPH的男性患者.
- 使用IPSS,生活质量,前列腺体积,余尿体积和Qmax来衡量有效性.
- 通过PCR确定了CYP2D6等位基变异 (*2, *3, *4, *6, *9, *10, *41).
主要成果:
- 较差和中等CYP2D6代谢剂在中度症状子组中显示显著更高的ΔQmax.
- CYP2D6*10和*41基因型,以及BMI和前列腺体积,与治疗疗效有关.
- CYP2D6的多态性并没有影响坦苏洛辛的安全性;多变量分析预测了92.1%的准确性.
结论:
- 基因标记物CYP2D6 (*4, *10, *41) 是tamsulosin有效性的潜在预测因素.
- 包括BMI和前列腺体积在内的非遗传因素也与tamsulosin治疗结果相关.
- 这些已识别的标记物可以帮助个性化对LUTS/BPH的tamsulosin治疗策略.
相关概念视频
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
72
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
72
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
41
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
41
01:27Nonlinear Pharmacokinetics: Role of Transporters
27
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
27
01:19Factors Affecting Drug Biotransformation: Biological
100
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
100
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131